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Background: The prevalence of novel type 1 diabetes mellitus (T1DM) antibodies targeting eukaryote translation elongation 
factor 1 alpha 1 autoantibody (EEF1A1-AAb) and ubiquitin-conjugating enzyme 2L3 autoantibody (UBE2L3-AAb) has been 
shown to be negatively correlated with age in T1DM subjects. Therefore, we aimed to investigate whether age affects the levels of 
these two antibodies in nondiabetic subjects.
Methods: EEF1A1-AAb and UBE2L3-AAb levels in nondiabetic control subjects (n=150) and T1DM subjects (n=101) in various 
ranges of age (18 to 69 years) were measured using an enzyme-linked immunosorbent assay. The cutoff point for the presence of 
each autoantibody was determined based on control subjects using the formula: [mean absorbance+3×standard deviation].
Results: In nondiabetic subjects, there were no significant correlations between age and EEF1A1-AAb and UBE2L3-AAb levels. 
However, there was wide variation in EEF1A1-AAb and UBE2L3-AAb levels among control subjects <40 years old; the preva-
lence of both EEF1A1-AAb and UBE2L3-AAb in these subjects was 4.4%. When using cutoff points determined from the con-
trol subjects <40 years old, the prevalence of both autoantibodies in T1DM subjects was decreased (EEFA1-AAb, 15.8% to 8.9%; 
UBE2L3-AAb, 10.9% to 7.9%) when compared to the prevalence using the cutoff derived from the totals for control subjects. 
Conclusion: There was no association between age and EEF1A1-AAb or UBE2L3-AAb levels in nondiabetic subjects. However, 
the wide variation in EEF1A1-AAb and UBE2L3-AAb levels apparent among the control subjects <40 years old should be taken 
into consideration when determining the cutoff reference range for the diagnosis of T1DM.
Keywords: Autoantibodies; Diabetes mellitus, type 1; Eukaryote translation elongation factor 1 alpha 1 autoantibody; Ubiquitin-
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INTRODUCTION
Type 1 diabetes mellitus (T1DM) results from immune medi-
ated destruction of pancreatic β-cells. The presence of autoan-
tibodies, such as anti-glutamic acid decarboxylase (GAD65) 
autoantibody (GADA), precedes clinical disease by months or 
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even years and persists after the disease becomes clinically 
overt [1,2]. GADA is used not only to diagnose autoimmune-
mediated T1DM, but also to predict the course of disease pro-
gression [3,4]. 
 We have recently reported on two novel autoantibodies 
found through exploration of T1DM autoantibody repertoires 
using protein microarrays [5]. These two autoantibodies, eu-
karyote translation elongation factor 1 alpha 1 autoantibody 
(EEF1A1-AAb) and ubiquitin-conjugating enzyme 2L3 auto-
antibody (UBE2L3-AAb), were detected in 40% of GADA 
negative T1DM patients as well as in patients with fulminant 
T1DM [5]. The prevalence of EEF1A1-AAb and UBE2L3-AAb 
increased as the age of disease onset decreased, whilst EEF1A1-
AAb and UBE2L3-AAb were only detected in T1DM patients 
<40 years old [5]. Given that age may be associated with auto-
antibody positivity in T1DM subjects, more studies are needed 
to determine whether the concentration of EEF1A1-AAb and 
UBE2L3-AAb in control subjects is also affected by age. Cutoff 
values for antibody positivity are typically set at the 99th per-
centile of antibody levels obtained from nondiabetic control 
subjects [6]; therefore, it is important to measure the level of 
these novel autoantibodies in nondiabetic control subjects over 
a broad range of ages. However, our previous investigation re-
garding these antibodies in control subjects across various age 
ranges was limited because of the unavailability of a sufficient 
pool of nondiabetic control subjects <40 years old.
 In this report, we aimed to investigate whether age affects 
the level of EEF1A1-AAb and UBE2L3-AAb in nondiabetic 
subjects and to confirm low levels of EEF1A1-AAb and UBE2L3- 
AAb in young, nondiabetic control subjects.
METHODS 
Sample preparation 
The control serum samples were obtained from nondiabetic 
control subjects ≥18 years old who had a fasting plasma glu-
cose concentration of <6.1 mmol/L and glycosylated hemo-
globin value of <5.8% (40.0 mmol/mol). To assure an even age 
distribution in the control sample, 20 samples were collected 
in each age group (i.e., 18 to 29, 30 to 39, 40 to 49, 50 to 59, and 
60 to 69 years). Age-matched serum samples from T1DM pa-
tients were also collected to compare the level of autoantibod-
ies with those of the control samples; T1DM samples were se-
lected as described in a previous report [5]. As we reported 
previously, EEF1A1-AAb and UBE2L3-AAb were detected 
only in T1DM patients <40 years old previously [5], and 50 
control samples from subjects <40 years old were added to 
compare the EEF1A1-AAb and UBE2L3-AAb levels between 
the age-matched control and T1DM groups (Table 1). GADA 
levels were determined using a commercially available radio-
immunoassay kit (RSR Ltd., Cardiff, UK) [7] recommended 
by the Diabetes Autoantibody Standardization Program [8].
Table 1. Prevalence of EEF1A1-AAb and UBE2L3-AAb by age group
Variable
No. (men %)
EEF1A1-AAb, % (number) UBE2L3-AAb, % (number)
Reference range 1a Reference range 2b Reference range 1c Reference range 2d
Control T1DM Control T1DM Control T1DM Control T1DM Control T1DM
Age, yr
   18–29 30 (46.7) 49 (53.1) 6.7 (2/30) 30.6 (15/49) 3.3 (1/30) 18.4 (9/49) 6.7 (2/30) 22.4 (11/49) 3.3 (1/30) 16.3 (8/49)
   30–39 60 (51.7) 28 (39.3) 3.3 (2/60)   3.6 (1/28) 1.7 (1/60) 0 3.3 (2/60) 0 3.3 (2/60) 0
   40–49 20 (50.0) 16 (68.8) 5.0 (1/20) 0 5 (1/20) 0 5.0 (1/20) 0 0 0
   50–59 20 (50.0) 6 (66.7) 0 0 0 0 5.0 (1/20) 0 5.0 (1/20) 0
   60–69 20 (50.0) 2 (0.0) 0 0 0 0 0 0 0 0
P for trendse - - 0.615 0.001 0.423 0.009 0.409 0.003 0.588 0.014
EEF1A1-AAb, eukaryote translation elongation factor 1 alpha 1 autoantibody; UBE2L3-AAb, ubiquitin-conjugating enzyme 2L3 autoanti-
body; T1DM, type 1 diabetes mellitus.
aReference range 1 was estimated from the total control subject sample (upper cutoff value was 1.418 for EEF1A1-AAb), bReference range 2 was 
estimated from control subjects <40 years old (upper cutoff value was 1.595 for EEF1A1-AAb), cReference range 1 was estimated from the total 
control subject sample (upper cutoff value was 2.512 for UBE2L3-AAb), dReference range 2 was estimated from control subjects <40 years old 
(upper cutoff value was 2.643 for UBE2L3-AAb), eDifference in the prevalence of autoantibodies according to age group using linear-by-linear 
association analysis. 
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 This study was conducted in accordance with the Declara-
tion of Helsinki provisions for the participation of subjects in 
human research. The Institutional Review Board of the Clini-
cal Research Institute at Seoul National University Hospital 
approved the study protocol. Written informed consent was 
obtained from each subject.
Enzyme-linked immunosorbent assay
Immunosorbent 96-well plates coated with EEF1A1 or UBE2L3 
(Origene Rockville, MD, USA) were incubated with diluted se-
rum samples (1:1,000 to 1:2,500) in phosphate-buffered saline 
buffer. All experiments were performed in triplicate for each 
sample. The recombinant proteins and their corresponding an-
tibodies, anti-EEF1A1 (Merck Millipore, Billerica, MA, USA) 
and anti-UBE2L3 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) were used as positive controls. Autoantibodies bound to 
the protein were detected with goat anti-human immunoglobu-
lin G-horseradish peroxidase (Jackson ImmunoResearch, West 
Grove, PA, USA). The experimental assay coefficient of vari-
ability (CV) from enzyme-linked immunosorbent assay (ELI-
SA) was calculated using the standard deviation divided by the 
mean (×100). The range of intra-assay CV was 8.4% to 10.2% 
for EEF1A1-AAb and 6.8% to 8.1% for UBE2L3-AAb, while the 
interassay CV was 24.1% for EEF1A1-AAb and 13.3% for 
UBE2L3-AAb. The cutoff point for the presence or absence of 
each autoantibody was determined using control subjects and 
according to the formula [mean absorbance+3 standard devia-
tion]. This corresponded approximately to 99% of the normal 
controls.
Statistical analysis
All data were analyzed with SPSS version 16 (SPSS Inc., Chica-
go, IL, USA). The results are presented as the mean±standard 
deviation. The differences in EEF1A1-AAb and UBE2L3-AAb 
levels stratified by age group were assessed using analysis of 
variance (ANOVA) test with post hoc comparisons using Bon-
ferroni’s method. A chi-square test was performed to evaluate 
differences in the proportion of antibody-positive subjects per 
group. Given the small number of cases in each group, a Mann-
Whitney test was used to compare the level of EEF1A1-AAb 
and UBE2L3-AAb between T1DM subjects and nondiabetic 
control subjects in each age group. 
 
RESULTS
Autoantibodies in the sera of 150 control subjects (mean age, 
41±13 years) were profiled. The levels of EEF1A1-AAb and 
UBE2L3-AAb were calculated using the mean values of two 
independent ELISA tests and each ELISA test was performed 
in triplicate. In the nondiabetic control sample, the mean 
EEF1A1-AAb level was 0.51±0.43 in subjects 18 to 29 years 
old, 0.39±0.36 in subjects 30 to 39 years old, 0.36±0.31 in sub-
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Fig. 1. The mean levels of (A) eukaryote translation elongation factor 1 alpha 1 autoantibody (EEF1A1-AAb) and (B) ubiquitin-
conjugating enzyme 2L3 autoantibody (UBE2L3-AAb) by age group. The mean values with standard deviation in each age group 
are shown. There were no differences in the levels of EEF1A1-AAb and UBE2L3-AAb across the age groups in control subjects 
(black circles). However, the levels of both autoantibodies in subjects that were 18 to 29 years old with type 1 diabetes mellitus 
(T1DM; black squares) were significantly higher than all of the other age groups (P<0.05) except for subjects 60 to 69 years old 
(black circles, nondiabetic control subjects; black squares, subjects with T1DM). aSignificantly different compared to nondiabetic 
control subjects in each age group (P<0.05), bSignificantly different compared to 18- to 29-year-old in each disease status (non-
diabetic control group and T1DM, respectively; P<0.05).
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jects 40 to 49 years old, 0.38±0.22 in subjects 50 to 59 years old, 
and 0.42±0.15 in subjects 60 to 69 years old. There were no sig-
nificant differences in EEF1A1-AAb levels across age groups (P 
from ANOVA=0.484 in EEF1A1-AAb) (Fig. 1). The level of 
UBE2L3-AAb also showed no differences across age groups 
(1.05±0.58, 0.90±0.55, 0.82±0.49, 0.97±0.56, 1.01±0.27, re-
spectively; P from ANOVA=0.541) (Fig. 1). In addition, there 
were no differences in EEF1A1-AAb and UBE2L3-AAb levels 
between control subjects <40 years old and those ≥40 years 
(P=0.387 and P=0.846, respectively). Significant correlations 
between age and the level of each autoantibody were not ob-
served among control subjects (r =−0.069, P =0.405 for 
EEF1A1-AAb; r=−0.005, P=0.951 for UBE2L3-AAb). Howev-
er, among T1DM subjects, EEF1A1-AAb and UBE2L3-AAb 
levels were significantly different across age groups (P from 
ANOVA <0.001 for both antibodies), supporting our previous 
research [5]. In addition, the levels of both autoantibodies were 
significantly higher in T1DM patients <40 years old compared 
to those ≥40 years old (P<0.001 for both autoantibodies). Fur-
thermore, the levels of both autoantibodies in T1DM subjects 
18 to 29 years old were significantly higher than all other age 
groups (P<0.05) except subjects 60 to 69 years old (Fig. 1). We 
subsequently compared EEF1A1-AAb and UBE2L3-AAb lev-
els between nondiabetic control subjects and T1DM subjects 
within each age group and found that both autoantibodies were 
significantly higher in T1DM subjects than control subjects 
that were 18 to 29 years old and 30 to 39 years old (P<0.001 for 
both age groups) (Fig. 1).
 Although there was no variation between age and the mean 
level of each autoantibody in nondiabetic control subjects, 
several individual control samples showed significantly high 
levels of EEF1A1-AAb or UBE2L3-AAb in subjects <40 years 
old (Fig. 2). Because the reference ranges for both autoanti-
bodies were determined from the standard deviation of the 
control group, reference range 1 was estimated using the entire 
control subject sample while the reference range 2 was esti-
mated using only control group subjects <40 years old. Using 
reference range 1, the prevalence of EEF1A1-AAb was 15.8% 
(16/101) in T1DM subjects and 3.3% (5/150) in control group 
subjects (P from chi-square test <0.001). Using reference range 
2, the prevalence was lower in both groups: 8.9% (9/101) in the 
T1DM group and 2.0% (3/150) in the control group (P from 
chi-square test=0.012). When using reference range 2 among 
T1DM patients, EEF1A1-AAb was detected only in patients 18 
to 29 years old. The prevalence in this age group was 18.4% 
(9/49) (Table 1). Similar results were found for UBE2L3-AAb. 
Using reference range 1, the prevalence of UBE2L3-AAb was 
10.9% (11/101) in T1DM subjects and 4.0% (6/150) in control 
subjects (P from chi-square test=0.033), while the prevalence 
decreased in both groups; i.e., 7.9% (8/101) in the T1DM group 
and 2.7% (4/150) in the control group, when using reference 
range 2. 
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Fig. 2. The level of (A) eukaryote translation elongation factor 1 alpha 1 autoantibody (EEF1A1-AAb) and (B) ubiquitin-conju-
gating enzyme 2L3 autoantibody (UBE2L3-AAb) in control and type 1 diabetes mellitus (T1DM) samples. Dotted lines repre-
sent the [mean absorbance+3×standard deviation] of the total nondiabetic control subject sample; dashed lines represent the 
[mean absorbance+3×standard deviation] of control subjects <40 years old; simple solid lines in each age group represent the 
mean level of EEF1A1-AAb and UBE2L3-AAb within the group (white circles, nondiabetic control subjects; black squares, sub-
jects with T1DM). 
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 None of the control subjects with EEF1A1-AAb or UBE2L3- 
AAb (reference range 1) had GADA. The mean age of control 
subjects with EEF1A1-AAb or UBE2L3-AAb was 34±10 and 
38±13 years, respectively. There was no difference in the mean 
age between control subjects with these autoantibodies when 
compared to control subjects without these autoantibodies. All 
of the control subjects with EEF1A1-AAb (n=5; reference 
range 1) also had UBE2L3-AAb, a finding consistent with our 
previous report [5].
DISCUSSION
To examine whether age affects EEF1A1-AAb and UBE2L3-
AAb levels in control samples, we compared the levels of both 
autoantibodies between age-stratified control and T1DM sam-
ples. This present study confirmed that there was no direct cor-
relation between the subjects’ age and the mean levels of 
EEF1A1-AAb and UBE2L3-AAb in control subjects. However, 
we detected the presence of several sporadic nondiabetic sub-
jects with high levels of those autoantibodies in the younger age 
groups; the prevalence of both EEF1A1-AAb and UBE2L3-AAb 
in control subjects <40 years old was 4.4%. As there was a wide 
range of variation in the levels of EEF1A1-AAb and UBE2L3-
AAb among young control subjects, reference ranges for those 
novel autoantibodies were increased for subjects <40 years old. 
Consequently, the prevalence of EEF1A1-AAb and UBE2L3-
AAb decreased in T1DM patients after applying the increased 
reference range. Nevertheless, the prevalence and the levels of 
EEF1A1-AAb and UBE2L3-AAb remained higher in the 
T1DM group compared to the nondiabetic control group. In 
addition, we confirmed that the levels of EEF1A1-AAb and 
UBE2L3-AAb were significantly higher in T1DM subjects com-
pared to control subjects even in younger adults <40 years old.
 We previously reported that the prevalence of EEF1A1-AAb 
was 29.5% for T1DM patients and 31.8% in GADA-negative 
T1DM patients [5], a rate that is comparable to that of ZnT8A 
in adult T1DM patients in Asian populations [9,10]. However, 
a wide range of variation in EEF1A1-AAb and UBE2L3-AAb 
levels in nondiabetic control subjects <40 years old, as ob-
served in this study, suggests a reduced prevalence of these au-
toantibodies in T1DM patients. In addition, given the very low 
prevalence of T1DM in the Korean population [11], the ob-
served prevalence of EEF1A1-AAb and UBE2L3-AAb in con-
trol subjects <40 years old in this study is relatively high. Thus, 
to assess the clinical usefulness of these autoantibodies for the 
detection of T1DM and to determine the reference range cutoff 
level for nondiabetic control subjects, additional studies with 
larger control populations <40 years old are needed.
 In the case of GADA, which is the most prevalent autoanti-
body among T1DM subjects, the prevalence in an unaffected 
population in Scandinavia was 2.4% to 4.7% [12-14]. In a simi-
larly unaffected population in the United States, the prevalence 
was 1.7% to 1.8% [15,16]. Although few studies have examined 
the association between GADA concentrations and age in the 
general population, the studies that exist have reported that 
healthy children had higher GADA levels than healthy adults 
[15,17], which are findings that are not consistent [18]. The 
clinical course of unaffected subjects with GADA is also un-
clear. For example, the Botnia Study reported that subjects with 
GADA had a significantly higher risk of developing type 2 as 
well as type 1 diabetes [14]; however, these results are not con-
sistent with the findings of another study [19]. 
 A major limitation of the current study is the absence of fol-
low-up data for control subjects. This limited our ability to de-
fine the clinical characteristics of control subjects with EEF1A1-
AAb or UBE2L3-AAb. Given that EEF1A1-AAb and UBE2L3-
AAb are found in unaffected control subjects <40 years old, 
long-term follow-up studies on whether these autoantibodies 
affect glucose metabolism in healthy subjects are needed. Fur-
thermore, EEF1A1 and UBE2L3 have been reported to be asso-
ciated with other autoimmune diseases such as rheumatoid ar-
thritis [20,21], Crohn disease [22], and systemic lupus erythe-
matosus [23] and both are also expressed in extra-pancreatic 
tissue [24-27]. Consequently, additional independent replica-
tion studies are needed to further explain the clinical implica-
tions of EEF1A1-AAb and UBE2L3-AAb in relation to the di-
agnosis of T1DM in larger populations with different demo-
graphics (e.g., age and ethnicity) as well as the presence of other 
autoimmune diseases.
 In conclusion, there was no association between age and the 
level of EEF1A1-AAb and UBE2L3-AAb in nondiabetic sub-
jects. However, the level of EEF1A1-AAb and UBE2L3-AAb 
varied widely among control subjects <40 years old and should 
be considered an important factor when determining the refer-
ence range for these autoantibodies.
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